What is the expected size of the U.S. Respiratory Syncytial Virus Vaccines market in 2026?

The market is expected to be valued at US$ 699.1 Million in 2026, projected to reach US$ 1,928.7 Million by 2033 at a CAGR of 15.6%, reflecting an absolute dollar opportunity of US$ 1,229.6 Million across the forecast period as newly approved vaccines expand across eligible patient populations nationwide.

What is the key factor driving demand for RSV vaccines in the U.S.?

Expanded ACIP recommendations covering older adults, pregnant individuals, and infants, combined with sequential FDA approvals of Arexvy, ABRYSVO, and mRESVIA, continue to drive sustained demand across hospital, pharmacy, and clinic administration settings each RSV season.

Which region leads the U.S. Respiratory Syncytial Virus Vaccines market?

The Southeast U.S. leads the market with 29% share in 2026, supported by dense hospital networks, high seasonal RSV circulation, and expanded state Medicaid coverage for maternal and infant immunization programs.

What is a key opportunity within the U.S. Respiratory Syncytial Virus Vaccines market?

mRNA platform expansion and growing retail pharmacy administration access represent significant opportunities, widening patient access, enabling faster next-generation formulation development, and supporting combination immunization visits during peak RSV season.

Who are the key players in the U.S. Respiratory Syncytial Virus Vaccines market?

Key players include Pfizer Inc., Sanofi, GlaxoSmithKline (GSK), AstraZeneca, Moderna, Inc., and Swedish Orphan Biovitrum (Sobi), alongside emerging developers such as Codagenix Inc. and Meissa Vaccines, Inc., among others.

Table of Content - U.S. Respiratory Syncytial Virus Vaccines Market Size, Share, and Growth Forecast 2026

Executive Summary
1. U.S. Respiratory Syncytial Virus Vaccines Market Snapshot 2026 and 2033
2. Market Opportunity Assessment, 2026-2033, US$ Mn
3. Key Market Trends
4. Industry Developments and Key Market Events
5. Demand Side and Supply Side Analysis
6. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definitions
2. Value Chain Analysis
3. Macro-Economic Factors
  1. U.S. GDP Outlook
  2. U.S. Sectorial Outlook
  3. U.S. GDP Growth Outlook
4. Forecast Factors – Relevance and Impact
5. COVID-19 Impact Assessment
6. PESTLE Analysis
7. Porter's Five Forces Analysis
8. Geopolitical Tensions: Market Impact
9. Regulatory and Technology Landscape
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
4. Trends
U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Drug
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Mn) Analysis by Drug, 2020-2025
  3. Current Market Size (US$ Mn) Forecast, by Drug, 2026-2033
    1. Palivizumab
    2. ABRYSVO (RSVpreF PF06928316)
    3. Arexvy - RSVPreF3 OA (GSK3844766A)
    4. mRESVIA (mRNA-1345)
    5. Janssen RSV Vaccine
    6. ResVax
    7. Nirsevimab (MEDI8897)
    8. MVA-BN RSV
  4. Market Attractiveness Analysis: Drug
3. U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Distribution Channel
  1. Introduction/Key Findings
  2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2020-2025
  3. Current Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
    1. Institutional Sales
      1. Hospitals
      2. Specialty Clinics
      3. Academic and Research Institutes
    2. Retail Sales
      1. Retail Pharmacy
      2. Drug Stores
    3. Online Sales
  4. Market Attractiveness Analysis: Distribution Channel
U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Zone
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis by Zone, 2020-2025
3. Current Market Size (US$ Mn) Forecast, by Zone, 2026-2033
  1. West U.S.
  2. Midwest U.S.
  3. Southwest U.S.
  4. Southeast U.S.
  5. Northeast U.S.
4. Market Attractiveness Analysis: Zone
West U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. West U.S. Market Size (US$ Mn) Forecast, by Drug, 2026-2033
  1. Palivizumab
  2. ABRYSVO (RSVpreF PF06928316)
  3. Arexvy - RSVPreF3 OA (GSK3844766A)
  4. mRESVIA (mRNA-1345)
  5. Janssen RSV Vaccine
  6. ResVax
  7. Nirsevimab (MEDI8897)
  8. MVA-BN RSV
3. West U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
  1. Institutional Sales
    1. Hospitals
    2. Specialty Clinics
    3. Academic and Research Institutes
  2. Retail Sales
    1. Retail Pharmacy
    2. Drug Stores
  3. Online Sales
Midwest U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Midwest U.S. Market Size (US$ Mn) Forecast, by Drug, 2026-2033
  1. Palivizumab
  2. ABRYSVO (RSVpreF PF06928316)
  3. Arexvy - RSVPreF3 OA (GSK3844766A)
  4. mRESVIA (mRNA-1345)
  5. Janssen RSV Vaccine
  6. ResVax
  7. Nirsevimab (MEDI8897)
  8. MVA-BN RSV
3. Midwest U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
  1. Institutional Sales
    1. Hospitals
    2. Specialty Clinics
    3. Academic and Research Institutes
  2. Retail Sales
    1. Retail Pharmacy
    2. Drug Stores
  3. Online Sales
Southwest U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Southwest U.S. Market Size (US$ Mn) Forecast, by Drug, 2026-2033
  1. Palivizumab
  2. ABRYSVO (RSVpreF PF06928316)
  3. Arexvy - RSVPreF3 OA (GSK3844766A)
  4. mRESVIA (mRNA-1345)
  5. Janssen RSV Vaccine
  6. ResVax
  7. Nirsevimab (MEDI8897)
  8. MVA-BN RSV
3. Southwest U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
  1. Institutional Sales
    1. Hospitals
    2. Specialty Clinics
    3. Academic and Research Institutes
  2. Retail Sales
    1. Retail Pharmacy
    2. Drug Stores
  3. Online Sales
Southeast U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Southeast U.S. Market Size (US$ Mn) Forecast, by Drug, 2026-2033
  1. Palivizumab
  2. ABRYSVO (RSVpreF PF06928316)
  3. Arexvy - RSVPreF3 OA (GSK3844766A)
  4. mRESVIA (mRNA-1345)
  5. Janssen RSV Vaccine
  6. ResVax
  7. Nirsevimab (MEDI8897)
  8. MVA-BN RSV
3. Southeast U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
  1. Institutional Sales
    1. Hospitals
    2. Specialty Clinics
    3. Academic and Research Institutes
  2. Retail Sales
    1. Retail Pharmacy
    2. Drug Stores
  3. Online Sales
Northeast U.S. Respiratory Syncytial Virus Vaccines Market Outlook: Historical (2020 – 2025) and Forecast (2026 – 2033)
1. Key Highlights
2. Northeast U.S. Market Size (US$ Mn) Forecast, by Drug, 2026-2033
  1. Palivizumab
  2. ABRYSVO (RSVpreF PF06928316)
  3. Arexvy - RSVPreF3 OA (GSK3844766A)
  4. mRESVIA (mRNA-1345)
  5. Janssen RSV Vaccine
  6. ResVax
  7. Nirsevimab (MEDI8897)
  8. MVA-BN RSV
3. Northeast U.S. Market Size (US$ Mn) Forecast, by Distribution Channel, 2026-2033
  1. Institutional Sales
    1. Hospitals
    2. Specialty Clinics
    3. Academic and Research Institutes
  2. Retail Sales
    1. Retail Pharmacy
    2. Drug Stores
  3. Online Sales
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping
  2. Competition Dashboard
3. Company Profiles
  1. Pfizer Inc.
    1. Company Overview
    2. Product Portfolio/Offerings
    3. Key Financials
    4. SWOT Analysis
    5. Company Strategy and Key Developments
  2. Sanofi
  3. GlaxoSmithKline (GSK)
  4. AstraZeneca
  5. Moderna, Inc.
  6. Swedish Orphan Biovitrum (Sobi)
  7. Codagenix Inc.
  8. Enanta Pharmaceuticals, Inc.
  9. Meissa Vaccines, Inc.
  10. Vaxart, Inc.
  11. Advaccine Biopharmaceuticals Co., Ltd.
  12. CyanVac LLC
  13. Intravacc B.V.
  14. Others
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

U.S. Respiratory Syncytial Virus Vaccines Market Size, Share, and Growth Forecast 2026 - 2033

U.S. Respiratory Syncytial Virus Vaccines Market by Drug (Palivizumab, ABRYSVO, Arexvy, mRESVIA, Janssen RSV Vaccine, ResVax, Nirsevimab, MVA-BN RSV), by Distribution Channel (Institutional Sales, Retail Sales, Online Sales), by Regional Analysis, 2026 - 2033

Quick Links

Our Partners

Secure Payments Through